Aspen Neuroscience Inc. ASPE · SEC Filings

website

117

Aspen Neuroscience, Inc. is a clinical-stage regenerative medicine biotechnology company, which enga...

Price12.4

Market Cap360.88 M

Float3.79 M

CountryUS

SectorHealthcare

ExchangeNASDAQ

Overview Filings Insights Dilution News Transcripts

Search in Documents

Open in Studio Login

TYPE

HEADLINE

FILED AT

TYPE

HEADLINE

FILED AT

TYPE

HEADLINE

FILED AT

TYPE

HEADLINE

FILED AT

Financials

TYPE

HEADLINE

FILED AT

News

TYPE

HEADLINE

FILED AT

8-K

Aspen Neuroscience, Inc. Completes Initial Public Offering and Adopts Amended Certificate of Incorporation and Bylaws

Nov 2, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B4

IPO | Offering amount: $140,625,000 | Shares: 9,375,000 | Price: $15.000 | Bank: Leerink Partners

Oct 30, 2026

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Nov 2, 2026

8-A12B

Form 8-A12B - Registration of securities [Section 12(b)]

Oct 29, 2026

S-1/A

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]

Oct 26, 2026

S-1/A

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]

Oct 22, 2026

S-1

Form S-1 - General form for registration of securities under the Securities Act of 1933

Oct 9, 2026

DRS/A

Form DRS/A - Draft Registration Statement: [Amend]

Jun 9, 2026

Proxies

TYPE

HEADLINE

FILED AT

Ownerships

TYPE

HEADLINE

FILED AT

SCHEDULE 13D

NEWARCH Venture Fund X, L.P. (Filed by)

Nov 9, 2026

NEWHasnain Faheem (Reporting)

Nov 9, 2026

SCHEDULE 13G

NEWFrazier Life Sciences X, L.P. (Filed by)

Nov 9, 2026

SCHEDULE 13D

ORBIMED ADVISORS LLC (Filed by)

Nov 6, 2026

SCHEDULE 13G

GILEAD SCIENCES, INC. (Filed by)

Nov 6, 2026

SCHEDULE 13G

FMR LLC (Filed by)

Nov 6, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Oct 30, 2026